Prakhyath Srikaram
@dr_prakhyaths
Heme-Onc Fellowship applicant | PGY3 Internal Medicine Resident - Baptist -NM | ASH/ASCO member | Kurnool Medical College Alumnus
ID: 1454390780290744320
30-10-2021 10:13:07
70 Tweet
78 Takipçi
329 Takip Edilen
Hello #MedTwitter Finally submitted my application. Thanks to all my mentors who supported me. I’m Prakhyath Srikaram, an ECMFG Certified Internal Medicine applicant,#Match2023 Looking forward to connecting with my fellow applicants, mentors and programs. Inside The Match
Mary Washington Healthcare Internal Medicine Program is hosting a virtual Open House. Join us to learn about our program’s focus on resident wellness, excellent education, and developing the highest quality physicians. Oct 4 @ 7pm. marywashingtonhealthcare.com/events-calenda… #residency #medstudent
🔈Attention all #Aspiringinternists 🔈Save the date! Upcoming Virtual open-house for #IMapplicants on October 25th, 2022!! Zoom link and details to follow next week! #IMProud #Match2023 #ERAS #IM Inside The Match Match A Resident®
🔊🔊 Attention all #Match2023 applicants! Join us for an open house next week on 10/25/22 at 5pm EST! #MedTwitter #MedEd #IMProud #ERAS Inside The Match Match A Resident® USMLE ERAS
Every morning I wake up gathering all the positivity, may be today! I’m still in hope for that day which proves my belief is true. 🥺 Inside The Match IMG_stories #MedTwitter #Match2023
#MedTwitter Join us as we go through selected highlights from the recent ASH 2024 meetings, educational webinar done by our rising #hemeonc fellowship applicants of 2025 Chalothorn “Sai” Wannaphut, MD Greeshma Gaddipati Prakhyath Srikaram #Leukemia #Malignantheme #Hematology #ash2024 #fellowship
Please stop by our poster CT 654 Society of Hematologic Oncology (SOHO) Thank you for your support and mentorship Dr. Jeremy Ramdial
Deeper and more durable responses may occur with cilta-cel compared with ide-cel in patients with relapsed or refractory multiple #myeloma, according to a meta-analysis led by Prakhyath Srikaram. ➡️ buff.ly/aYwXXqU
Revumenib is now U.S. FDA ✅ for R/R AML w/ NPM1 mutation (approved for KMT2A translocation previously). - ORR 46.9% - Response seen in all subgroups (comutations, previous HSCT, or high number of prior lines of Rx). #HemeTwitter Dr. Uma Borate: Associate Professor Joshua Zeidner MD 👏👏